Adaptive Biotechnologies Corp vs iShares TIPS Bond ETF — how do they compare? Adaptive Biotechnologies Corp trades at $25.69 (market cap $4.05B), while iShares TIPS Bond ETF trades at $106.9. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, iShares TIPS Bond ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | TIP | |
|---|---|---|
Market Cap | $4.05B | — |
Sector | Health | Fixed Income |
52-Week High | $25.45 | $112.20 |
52-Week Low | $12.30 | $106.86 |
Enterprise Value | $4.12B | — |
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.93, up 5.64% in 24 hours and near its 52-week high. The stock shows bullish technical momentum with improving fundamentals as revenue grew 55% year-over-year to $277M in 2025 while net losses narrowed significantly from -$159M to -$59M. The company's strategic shift to focus on its profitable MRD diagnostics business through a planned separation of Immune Medicine operations has driven investor optimism.
Outlook remains cautiously optimistic as ADPT transitions to a pure-play MRD company with strong gross margins exceeding 75%. While analyst consensus favors Buy ratings (65%), persistent net losses and high valuation multiples (P/S 12.6x, P/B 27.8x) present risks. The $25.50 price target suggests limited upside from current levels amid execution risks.
TIP trades at $107.08 with minimal daily movement (+0.2%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators are neutral. The stock faces headwinds from broader market concerns about inflation and Federal Reserve policy. Recent dividend distributions provide some shareholder return, but key financial ratios remain undisclosed, limiting fundamental visibility.
Outlook remains cautious due to bearish technicals and macroeconomic uncertainty. Investment opportunity hinges on inflation trends and Fed policy clarity, while risks include prolonged bond market volatility and energy price impacts. Wall Street sentiment appears mixed with technical weakness offset by dividend stability.
Trailing returns across standard periods
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →TIP is the flagship ETF for U.S. Treasury Inflation-Protected Securities (TIPS). It tracks an index of government bonds whose principal value adjusts based on the Consumer Price Index (CPI), providing a direct hedge against rising inflation.
Read more on TIP →